CMA closes probe into three Concordia drugs
The UK’s competition enforcer has shuttered part of its antitrust probe of drugmaker Concordia after deciding it did not have the need or resources to continue investigating three of the company’s drugs.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.